Although literatures have revealed overexpression of CacyBP in many cancers and its association with poor prognosis [26–33], the impact of CacyBP expression on the immune microenvironment, especially on regulating TAMs, remains poorly defined. The gene discussed is CACYBP; the disease is cancer.